Arch Biopartners Retains Virtus Advisory to Provide Investor Relations Services
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 10/21/15 -- Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE: ACH)(OTCBB: FOIFF), today announced that it has retained Virtus Advisory Group Inc. ("Virtus"), to develop and implement a strategic investor relations program, which includes enhancing the Company's exposure among industry stakeholders and investors across Canada.
In connection with the engagement (the "Agreement"), Virtus has been awarded a consulting contract for a monthly fee of $5,500. In addition, Virtus will be granted incentive stock options, the number of which will be determined by the board of directors, subject to the provisions of the Company's stock option plan and the policies of the TSX Venture Exchange.
The Company's engagement of Virtus is subject to the acceptance of the TSX Venture Exchange.
About Virtus Advisory Group
Virtus is a Toronto-based consulting firm, providing select private and publicly listed companies with business consulting, capital markets strategy and investor relations services. The company provides expert counsel and access to an unmatched network of investors and capital markets professionals across Canada and the United States. Virtus helps issuers establish the relationships and the investor confidence required to build long-term shareholder value. Visit for more information.
About Arch Biopartners
Arch Biopartners is a portfolio-based biotechnology company established to develop new products and technology for unmet medical needs. The Company's portfolio includes MetaMx, which targets brain tumor initiating cells; ABP569, a new treatment for respiratory P. aeruginosa infections; and, Metablok, a potential treatment for sepsis and cancer metastasis. Arch has also been developing its peptide-solid surface interface with the objective of reducing corrosion, biofilm formation and improving biocompatibility of various metals and plastics. For more information on the Company, please visit or consult public documents filed on SEDAR at .
Forward-Looking Statements
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Arch Biopartners, Inc.
Richard Muruve
Chief Executive Officer
647-428-7031
Virtus Advisory Group Inc.
Babak Pedram
Investor Relations
416-644-5081
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.10.2015 - 13:14 Uhr
Sprache: Deutsch
News-ID 428485
Anzahl Zeichen: 0
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 266 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Arch Biopartners Retains Virtus Advisory to Provide Investor Relations Services"
steht unter der journalistisch-redaktionellen Verantwortung von
Arch Biopartners Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
